Search > Results
You searched for: EV220049 (EV-TRACK ID)
Showing 1 - 5 of 5
Showing 1 - 5 of 5
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV220049 | 1/5 | Homo sapiens | CSF | (d)(U)C | Stuendl A | 2016 | 33% | |
Study summaryFull title
All authors
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A
Journal
Brain
Abstract
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological ag (show more...)
EV-METRIC
33% (78th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
CSF
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: Flotillin2/ alpha-synuclein/ IgG2
non-EV: Calnexin Proteomics
no
Show all info
Study aim
Function/Biomarker
Sample
Species
Homo sapiens
Sample Type
CSF
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: speed (g)
100000
Wash: time (min)
60
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
Not determined
Western Blot
Antibody details provided?
No
Detected EV-associated proteins
Flotillin2
Not detected EV-associated proteins
IgG2
Not detected contaminants
Calnexin
ELISA
Antibody details provided?
No
Detected EV-associated proteins
alpha-synuclein
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Not Reported
EV concentration
Yes
EM
EM-type
Transmission-EM
Image type
Close-up
Report size (nm)
40-120
|
||||||||
EV220049 | 2/5 | Homo sapiens | CSF | (d)(U)C | Stuendl A | 2016 | 0% | |
Study summaryFull title
All authors
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A
Journal
Brain
Abstract
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological ag (show more...)
EV-METRIC
0% (median: 12% of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
CSF
Sample origin
Parkinson`s disease
Focus vesicles
exosome
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: alpha-synuclein
non-EV: None Proteomics
no
Show all info
Study aim
Function/Biomarker
Sample
Species
Homo sapiens
Sample Type
CSF
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: speed (g)
100000
Wash: time (min)
60
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
Not determined
ELISA
Antibody details provided?
No
Detected EV-associated proteins
alpha-synuclein
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Not Reported
EV concentration
Yes
|
||||||||
EV220049 | 3/5 | Homo sapiens | CSF | (d)(U)C | Stuendl A | 2016 | 0% | |
Study summaryFull title
All authors
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A
Journal
Brain
Abstract
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological ag (show more...)
EV-METRIC
0% (median: 12% of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
CSF
Sample origin
Lewy body dementia
Focus vesicles
exosome
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: alpha-synuclein
non-EV: None Proteomics
no
Show all info
Study aim
Function/Biomarker
Sample
Species
Homo sapiens
Sample Type
CSF
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: speed (g)
100000
Wash: time (min)
60
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
Not determined
ELISA
Antibody details provided?
No
Detected EV-associated proteins
alpha-synuclein
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Not Reported
EV concentration
Yes
|
||||||||
EV220049 | 4/5 | Homo sapiens | CSF | (d)(U)C | Stuendl A | 2016 | 0% | |
Study summaryFull title
All authors
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A
Journal
Brain
Abstract
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological ag (show more...)
EV-METRIC
0% (median: 12% of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
CSF
Sample origin
Progressive supranuclear plasy
Focus vesicles
exosome
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: alpha-synuclein
non-EV: None Proteomics
no
Show all info
Study aim
Function/Biomarker
Sample
Species
Homo sapiens
Sample Type
CSF
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: speed (g)
100000
Wash: time (min)
60
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
Not determined
ELISA
Antibody details provided?
No
Detected EV-associated proteins
alpha-synuclein
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Not Reported
EV concentration
Yes
|
||||||||
EV220049 | 5/5 | Homo sapiens | CSF | (d)(U)C | Stuendl A | 2016 | 0% | |
Study summaryFull title
All authors
Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A
Journal
Brain
Abstract
Extracellular α-synuclein has been proposed as a crucial mechanism for induction of pathological ag (show more...)
EV-METRIC
0% (median: 12% of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
CSF
Sample origin
Polyneuropathy
Focus vesicles
exosome
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Protein markers
EV: alpha-synuclein
non-EV: None Proteomics
no
Show all info
Study aim
Function/Biomarker
Sample
Species
Homo sapiens
Sample Type
CSF
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: speed (g)
100000
Wash: time (min)
60
Wash: speed (g)
100000
Characterization: Protein analysis
Protein Concentration Method
Not determined
ELISA
Antibody details provided?
No
Detected EV-associated proteins
alpha-synuclein
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Not Reported
EV concentration
Yes
|
||||||||
1 - 5 of 5 |
EV-TRACK ID | EV220049 | ||||
---|---|---|---|---|---|
species | Homo sapiens | ||||
sample type | CSF | ||||
condition | Control condition | Parkinson`s disease | Lewy body dementia | Progressive supranuclear plasy | Polyneuropathy |
separation protocol | dUC | dUC | dUC | dUC | dUC |
Exp. nr. | 1 | 2 | 3 | 4 | 5 |
EV-METRIC % | 33 | 0 | 0 | 0 | 0 |